Skip to Content

The CHASIT Study Explores New Treatment Approach for Advanced Urothelial Cancer

The CHASIT study assumes that utilizing sequential chemo-immunotherapy may yield a pCR rate of ≥30% in treating patients with locally advanced, unresectable, or clinically node-positive urothelial cancer (UC) at stage cT4NxM0 or cTxN1-N3M0, surpassing the historical 15% pCR rate with induction chemotherapy.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top